Liao Duanfang, born in May 1959, is a doctor, professor, and doctoral supervisor. He currently serves as the president of Hunan University of Chinese Medicine and the deputy director of the State Key Laboratory (Cultivation) of "Traditional Chinese Medicine Powder and Innovative Drugs", and is the leader of the key discipline of Pharmacy in Hunan Province.
In 1985, he graduated from the Department of Medicine at Hengyang Medical College and obtained a medical bachelor's degree; in 1989, he graduated from the School of Pharmacy, Central South University, majoring in Pharmacology, and obtained a master's degree; in 2001, he graduated from the School of Pharmacy, Sun Yat - sen University, majoring in Pharmacology, and obtained a doctorate. In 1993, he was promoted to associate professor by special assessment. He began to enjoy the special government allowance in 1994, was selected as an outstanding young and middle - aged expert in Hunan Province in 1995, was selected as one of the first - batch of cross - century discipline leaders in Hunan Province in 1999, was selected as an expert of the Discipline Review Group of the Life Sciences Department of the National Natural Science Foundation of China in 2004, and was selected as a first - level candidate of the 121 Talent Project in Hunan Province in 2007. He has visited the University of Washington in the United States, the University of British Columbia in Canada, and the University of Rochester in the United States for further studies three times. In 2002, he was rated as an outstanding returned overseas student in Hunan Province, and in 2007, he won the Second "Science and Technology Innovation Talent Award" of the All - China Federation of Returned Overseas Chinese. In 2012, he was rated as an outstanding scientific and technological worker nationwide by the China Association for Science and Technology. He currently serves as the editor - in - chief of Current Traditional Medicine, the deputy editor - in - chief of Chinese Journal of Arteriosclerosis; the vice - chairman of the Chinese Chapter of the International Atherosclerosis Society, the vice - chairman of the Traditional Chinese Medicine Professional Committee of the World Federation of Chinese Medicine Societies, the standing director of the Chinese Chapter of the International Society of Heart Research, the standing director of the Chinese Cardiovascular Pharmacology Professional Committee, the standing director of the China Association of Chinese Medicine, the standing director of the Basic Theory Professional Committee of the Chinese Association of Integrative Medicine, the vice - chairman of the Hunan Pathophysiology Society, the vice - chairman of the Hunan Pharmaceutical Association, the vice - chairman of the Hunan Traditional Chinese Medicine Association, and the deputy director of the Special Expert Committee of the Hunan Federation of Returned Overseas Chinese.
He has long been committed to the research on vascular biology and the pathogenesis of atherosclerosis. He has conducted in - depth research on the relationship between cholesterol accumulation, transmembrane transport, and inflammation in lipid - loaded cells. He proposed a working model of "four systems, one center, coupled transport, and network regulation" for the outward transport of cholesterol in lipid - loaded cells. He has systematically studied the cardiovascular pharmacological effects of nicotinate - curcumin ester. He clarified the Ras→PKC－ζ→MEK→ERK1/2→p70S6K signaling pathway by which angiotensin II stimulates the proliferation of smooth muscle cells; discovered that oxidative stress can stimulate vascular smooth muscle cells to release the SOXF factor and isolated and purified this factor. He jointly established a mutation - sensitive molecular switch technology based on primer sulfide modification combined with high - fidelity DNA polymerase - mediated gene mutation. He participated in the establishment of an atherosclerosis model of Guizhou miniature pigs fed with a high - sugar and high - fat diet. He systematically studied the role of the aldoketoreductase - like AKR1B family in the occurrence of colitis/cancer by affecting the synthesis of long - chain fatty acids.
He has successively presided over 8 projects of the National Natural Science Foundation of China, 1 project of the International Youth Fund of the Japanese Heart Association, and nearly 30 projects such as those of the Ministry of Education, the Ministry of Health, the Natural Science Foundation of Hunan Province, major and key projects in Hunan Province, and sub - projects of the 863 Program. He has also participated in 2 projects of the National 973 Program. He has published more than 270 papers in domestic and foreign journals such as Circ Res, J Biol Chem, J Lipid Res, Eur J Pharmacol, Life Sci, BBRC, CEPP, Mol Biotech, Int J Cancer, PloS One, Atherosclerosis, and Acta Pharmacol Sin, among which more than 120 papers are included in SCI, with a total impact factor (IF) of over 400 points, and have been positively cited by others for more than 1,500 times, with the highest single - paper citation exceeding 120 times. He has also published more than 40 teaching and research papers. He has successively won 1 first - prize of the Science and Technology Progress Award of the State Education Commission, 1 second - prize of the Natural Science Award of the Ministry of Education, 2 second - prizes and 4 third - prizes of the Science and Technology Progress Award in Hunan Province; 1 second - prize of the National Teaching Achievement Award, 1 first - prize and 1 second - prize, and 4 third - prizes of the Provincial Teaching Achievement Award; and has applied for 10 invention patents. He has edited or participated in editing 15 textbooks and monographs.
